LAUSR

Dear Editors, Direct oral anticoagulants (DOACs) are more and more used for the prevention of stroke in patients with atrial fibrillation (AF) and for the prevention and treatment of venous thromboembolism. The DOACs are also known to impact coagulation assays and enhance factor X (FX)dependent fibrinolysis and plasmin generation.1 Three methods including the thromboelastometry (TEG/ ROTEM), the thrombin generation assay (TGA), and the clot waveform analysis (CWA) are able to monitor the formation of thrombin or fibrin and recognized to reflect complete processes of coagulation and/or fibrinolysis.1,2 Lately, the clotfibrinolysis waveform analysis (CFWA), an extension of conventional CWA using tPA, allows the simultaneous analysis of clotting and fibrinolysis processes. In most studies, coagulation phase was triggered by using activated partial thromboplastin time (aPTT) reagent and CaCl2. 1,3